抗肥胖藥物市場規模、佔有率、成長分析（按藥物類型、作用、劑量和地區分類）- 產業預測，2025 年至 2032 年

2023 年全球減肥藥市場規模價值 37 億美元，預計將從 2024 年的 46.7 億美元成長到 2032 年的 302.6 億美元，預測期內（2025-2032 年）的複合年成長率為 26.3%。

世界肥胖聯合會預測，2025年終，肥胖相關成本將飆升50%以上，達到約1.2兆美元。這一激增凸顯了製藥業對於開發有效的肥胖解決方案的重視。隨著患者數量的成長和治療率仍然較低，新參與企業面臨著巨大的機會。肥胖意識舉措和支持性報銷政策的建立可能會推動對該產品的需求。 COVID-19 疫情反而促進了已通過核准的減肥藥物的銷售量，因為與肥胖相關的健康風險日益增加，促使衛生組織發布管理指南。此外，由於封鎖而導致久坐行為的增加可能會加劇對肥胖症治療的需求，從而促進市場成長。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 專利分析
• 監管分析

抗肥胖藥物市場規模（依藥物類型分類）

• 市場概況
• 處方藥
• 非處方藥

抗肥胖藥物市場規模（依功能分類）

• 市場概況
• 中樞抗肥胖藥物
• 外周作用抗肥胖藥物

抗肥胖藥物市場規模（按劑量）

• 市場概況
• 口服
• 皮下

減肥藥市場規模（依分銷管道分類）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

減肥藥市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Novo Nordisk A/S（Denmark）
• Eli Lilly and Company（USA）
• Roche Holding AG（Switzerland）
• Pfizer Inc.（USA）
• Currax Pharmaceuticals LLC（USA）
• Boehringer Ingelheim International GmbH（Germany）
• Amgen Inc.（USA）
• AstraZeneca PLC（UK/Sweden）
• GlaxoSmithKline plc（UK）
• Sanofi SA（France）
• Rhythm Pharmaceuticals, Inc.（USA）
• Gelesis Holdings, Inc.（USA）
• Merck & Co., Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Eisai Co., Ltd.（Japan）
• Orexigen Therapeutics, Inc.（USA）
• Zafgen Inc.（USA）（Ceased operations）
• VIVUS LLC（USA）（Acquired by Currax Pharmaceuticals）
• Cheplapharm Arzneimittel GmbH（Germany）
• KVK Tech Inc.（USA）

結論和建議

Global Anti Obesity Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 30.26 billion by 2032, growing at a CAGR of 26.3% during the forecast period (2025-2032).

The World Obesity Federation forecasts that obesity-related costs will surge by over 50%, reaching approximately $1.2 trillion by the end of 2025. This escalation emphasizes the pharmaceutical industry's focus on developing effective solutions to combat obesity. As the patient population grows and treatment rates remain low, there are significant opportunities for new entrants in the market. Initiatives aimed at educating the public about obesity and the establishment of supportive reimbursement policies are likely to drive product demand. The COVID-19 pandemic has paradoxically boosted sales of approved anti-obesity medications, as heightened health risks associated with obesity have prompted health organizations to issue management guidelines. Furthermore, increased sedentary behavior due to lockdowns has intensified the need for obesity treatments, potentially enhancing market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti Obesity Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti Obesity Drugs Market Segmental Analysis

Global Anti Obesity Drugs Market is segmented by Drug Type, Action, Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Prescription Drug and Over the Counter Drugs. Based on Action, the market is segmented into Centrally Acting Anti-Obesity Drugs and Peripherally Acting Anti-Obesity Drugs. Based on Administration, the market is segmented into Oral Route and Subcutaneous Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti Obesity Drugs Market

The global anti-obesity drugs market is significantly driven by escalating concerns regarding effective obesity management, propelled by the alarming rise in obesity rates among populations worldwide. Currently, the World Obesity Federation reports staggering figures of approximately 650 million adults and 120 million children grappling with obesity, leading to an annual expenditure of around US$ 2 trillion for obesity-related healthcare. Furthermore, the Centers for Disease Control and Prevention (CDC) indicates that 42.5% of adults in the United States are classified as obese. This escalating awareness, particularly in emerging economies, about the necessity of timely weight management is anticipated to further fuel the demand for anti-obesity medications in the market over the coming years.

Restraints in the Global Anti Obesity Drugs Market

The Global Anti-Obesity Drugs market faces significant restraints, despite the increasing prevalence of obesity worldwide. Treatment rates remain low, primarily due to a lack of awareness regarding weight management and widespread misconceptions about obesity. Our research indicates that only 2% of individuals with obesity receive prescription medication for their condition, reflecting low acceptance of these drugs, which hampers market growth. Additionally, the market is constrained by the limited number of key companies focused on developing obesity treatments and the adverse effects associated with these medications, further impeding broader adoption and expansion of anti-obesity solutions.

Market Trends of the Global Anti Obesity Drugs Market

The Global Anti-Obesity Drugs market is witnessing a significant trend towards the development of dual-action therapeutic compounds aimed at simultaneously addressing both Type 2 diabetes mellitus and obesity. This burgeoning focus is driven by the alarming increase in obesity rates and the corresponding prevalence of Type 2 diabetes, prompting pharmaceutical companies and researchers to innovate and create effective medications that tackle these interrelated health issues. With unhealthy dietary habits, sedentary lifestyles, and a growing obese population persisting as key challenges, the market is poised for substantial growth in the coming years, presenting lucrative opportunities for stakeholders in the healthcare sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis

Global Anti Obesity Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Prescription Drug
• Over the Counter Drugs

Global Anti Obesity Drugs Market Size by Action & CAGR (2025-2032)

• Market Overview
• Centrally Acting Anti-Obesity Drugs
• Peripherally Acting Anti-Obesity Drugs

Global Anti Obesity Drugs Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Oral Route
• Subcutaneous Route

Global Anti Obesity Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Anti Obesity Drugs Market Size & CAGR (2025-2032)

• North America (Drug Type, Action, Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Action, Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Action, Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Action, Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Action, Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Currax Pharmaceuticals LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK/Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gelesis Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orexigen Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zafgen Inc. (USA) (Ceased operations)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VIVUS LLC (USA) (Acquired by Currax Pharmaceuticals)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cheplapharm Arzneimittel GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KVK Tech Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations